Polaris doses first pediatric patient with ADI-PEG 20


Polaris Group is announcing that they have dosed the first patient in the company's Phase I safety and efficacy clinical trial in the evaluation of their oncology candidate, pegylated arginine deiminase (ADI-PEG 20).

ADI-PEG 20 is being investigated as a treatment against pediatric cases of lymphoma, leukemia and some sarcomas.

The trial is being carried out at MD Anderson Cancer Center in Texas.

Said John Bomalaski, M.D., Polaris' Executive Vice President of Medical Affairs, "We are delighted to begin this first study of ADI-PEG 20 in pediatric patients. We believe ADI-PEG 20 is a promising cancer therapeutic for these cancers, and we plan to initiate Phase 2 studies in adults with these cancers."

ADI-PEG 20 is currently being investigated as a monotherapy in a Phase III trial against hepatocellular carcinoma; Phase II trials against small cell lung carcinoma and mesothelioma; and a Phase I trial in combination with docetaxel against prostate cancer

Source: MarketWatch

LymphomaInfo Social